Red wine and green tea flavonoids are cis-allosteric activators and competitive inhibitors of GLUT1-mediated sugar uptake by Ojelabi, Ogooluwa A. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2018-10-25 
Red wine and green tea flavonoids are cis-allosteric activators 
and competitive inhibitors of GLUT1-mediated sugar uptake 
Ogooluwa A. Ojelabi 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Amino Acids, Peptides, and Proteins Commons, Biochemistry Commons, Carbohydrates 
Commons, Cellular and Molecular Physiology Commons, Molecular Biology Commons, and the Structural 
Biology Commons 
Repository Citation 
Ojelabi OA, Lloyd KP, De Zutter JK, Carruthers A. (2018). Red wine and green tea flavonoids are cis-
allosteric activators and competitive inhibitors of GLUT1-mediated sugar uptake. Open Access Articles. 
https://doi.org/10.1074/jbc.RA118.002326. Retrieved from https://escholarship.umassmed.edu/oapubs/
3637 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Red wine and green tea flavonoids are cis-allosteric activators and competitive inhibitors of 
GLUT1-mediated sugar uptake 
By 
Ogooluwa A. Ojelabi, Kenneth P. Lloyd, Julie K. De Zutter and Anthony Carruthers 
From the Department of Biochemistry and Molecular Pharmacology, Graduate School of Bio-
medical Sciences, University of Massachusetts Medical School, Worcester, Massachusetts, 01605 
Running title: Flavonoids are exofacial, GLUT1 ligands 
Address correspondence to: Anthony Carruthers, PhD., 364 Plantation Street, LRB Room 926 
Worcester, MA 01605. Phone: 508-856-5570; Fax: 508-856-6464; E-mail: 
anthony.carruthers@umassmed.edu 
Keywords: glucose transport; structure-function; membrane transport; allosteric regulation, 
oligomerization 
Abstract 
The anti-oxidant, flavonoid-rich content of red 
wine and green tea is reported to offer protec-
tion against cancer, cardiovascular disease and 
diabetes. Some studies, however, show that 
flavonoids inhibit GLUT1-mediated, facilita-
tive glucose transport raising the possibility 
that their interaction with GLUT1 and subse-
quent, downstream effects on carbohydrate 
metabolism may also impact health. The 
present study explores the structure/function 
relationships of flavonoid-GLUT1 interac-
tions. We find that low concentrations of 
flavonoids act as cis-allosteric activators of 
sugar uptake while higher concentrations 
competitively inhibit sugar uptake and non-
competitively inhibit sugar exit. Studies with 
heterologously expressed human GLUTs 1, 3 
and 4 reveal that quercetin-GLUT1 and -
GLUT4 interactions are stronger than 
quercetin-GLUT3 interactions, that ECG is 
more selective for GLUT1 while EGCG is less 
isoform-selective. Docking studies suggest 
that only one flavonoid can bind to GLUT1 at 
any instant, but sugar transport and ligand 
binding studies indicate that human erythro-
cyte GLUT1 can bind at least two flavonoid 
molecules simultaneously. Quercetin and 
EGCG are each characterized by positive, co-
operative binding whereas EGC shows nega-
tive cooperative binding. These findings sup-
port recent studies suggesting that GLUT1 
forms an oligomeric complex of interacting, 
allosteric, alternating access transporters. We 
discuss how modulation of facilitative glucose 
transporters could contribute to the protective 
actions of the flavonoids against diabetes and 
Alzheimer’s. 
Moderate consumption of red wine or green 
tea is associated with protection against can-
cer, cardiovascular disease and diabetes (1–4). 
These benefits are hypothesized to result from 
the flavonoid-rich, antioxidant capacity of the 
beverages (5). The present study investigates 
an alternative pathway by which the 
flavonoids may impact organismal health - 
direct interaction with the facilitative glucose 
transporters GLUT1, GLUT3 and GLUT4 
leading to downstream effects on carbohydrate 
metabolism.  
The flavonoids are a large group of polyphe-
nolic secondary metabolites with over 4,000 
types identified in fruits, flowers, vegetables 
and leaves (5, 6). The general structure of 
flavonoids is a flavan backbone (Figure 1A) 
consisting of 2 benzene rings linked together 
by a heterocyclic pyran ring (7). Substitutions 
in the flavan structure by hydroxyls, methyl 
groups and sugars create the wide range of 
flavonoid derivatives (5). Quercetin, epigallo-
catechin gallate (EGCG) and epicatechin gal-
late (ECG) are present in red wine and green 
tea and are among the most extensively char-
acterized flavonoids. Each cup of green tea is 
estimated to contain up to 300 mg EGCG, 49 
mg ECG and 14 mg quercetin (8–10). Red 
wine contains 4–16 mg/L quercetin (11, 12) 
but while EGCG and ECG are known to 
present in red wine (8) their levels are not well 
defined. The health benefits of the flavonoids 
have been attributed to their strong anti-oxi-
dant capacity. The flavonoids chelate metal 
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ions such as Fe3+, and trap reactive species 
including singlet oxygen, superoxide radicals, 
nitric oxide, and peroxynitrite (5, 13, 14). 
Some studies, however, show that quercetin, 
EGCG and ECG inhibit GLUT1-mediated 
facilitative glucose transport (15, 16) raising 
the possibility that it is their interaction with 
GLUT1 and their downstream effects on car-
bohydrate metabolism that impact health. 
While this may explain their actions in cancer 
where GLUT1 expression and non-oxidative 
glucose metabolism are upregulated (17), it is 
harder to understand how sugar transport inhi-
bition would ameliorate diabetes and cardio-
vascular disease. 
Recent studies have suggested that GLUT1 
forms an oligomer complex of interacting, 
allosteric, alternating access transporters (18, 
19) and that low concentrations of GLUT1 
inhibitors acting at exofacial or endofacial 
sugar binding sites stimulate sugar transport 
(18, 20).  The present study explores the de-
tailed structure/function relationships of 
flavonoid-GLUT1 interactions in order to ex-
plicate flavonoid action on cellular function. 
We find that the flavonoids act as heterotropic, 
cis-allosteric activators of sugar uptake at low 
concentrations and as competitive inhibitors of 
sugar uptake at higher concentrations. While 
some health benefits of flavonoids may indeed 
derive from their anti-oxidant capacities, fu-
ture studies should also consider how the dual 
actions of flavonoids on glucose transport may 
influence downstream glucose metabolism in 
tumors, in insulin-secreting and responsive 
tissues and in the CNS. 
Results 
Dietary flavonoids are reported to impair cel-
lular sugar transport to varying degrees in dif-
ferent cell types (16, 21–25). We therefore 
examined the effects of quercetin, EGCG and 
ECG (Figures 1B-1D) on GLUT1-mediated, 
zero-trans uptake of 3-O-methylglucose 
(3MG, a transported but non-metabolized sug-
ar) in human red blood cells. Quercetin, 
EGCG and ECG inhibit uptake of 0.1 mM 
3MG in a dose-dependent manner, with Ki(app) 
= 1.88 ± 0.33 µM, 9.63 ± 1.95 µM, and 1.90 ± 
0.32 µM respectively (Figure 1E). 
We determined the sidedness of flavonoid ac-
tion on GLUT1 by examining their effects on 
2 modes of red cell sugar transport: 1) zero-
trans 3MG uptake (influx into sugar-free 
cells), and 2) zero-trans 3MG exit (efflux from 
sugar-loaded cells into medium lacking sugar). 
Transport theory informs us (26, 27) that a 
ligand competing with sugar for binding at the 
exofacial sugar binding site serves as a com-
petitive inhibitor of sugar uptake and as a non-
competitive inhibitor of sugar exit. Converse-
ly, a ligand competing with sugar for binding 
at the endofacial sugar binding site serves as a 
noncompetitive inhibitor of sugar uptake and 
as a competitive inhibitor of exit. 
The effects of the flavonoids on the concentra-
tion-dependence of initial rates of 3MG uptake 
are shown in Figure 2A. Using the Extra Sum 
of Squares F-test (28) to test the null hypothe-
sis that 3MG uptake is described equally well 
by non-saturable sugar uptake (uptake = 
k*[S]), by Michaelis-Menten uptake (Equation 
2) and by Michaelis-Menten uptake plus non-
saturable uptake fails for all conditions. All 
uptakes are best described by simple 
Michaelis-Menten kinetics. Analysis of 3MG 
uptakes by non-linear regression analysis us-
ing equation 2 reveals that the flavonoids in-
crease Km(app) for sugar uptake from 2.39 ± 
0.36 mM to 11.07 ± 5.03 mM (quercetin), 
10.64 ± 2.63 mM (EGCG) and 7.14 ± 2.63 
mM (ECG), without significantly affecting 
Vmax for uptake (1.202 ± 0.082 mmol/L cell 
water/min; Figure 2A; Table 1). Lineweaver-
Burk analysis results in lower estimates of 
Vmax and Km(app) (Figure 2A inset and Table 1) 
but the same conclusion (Vmax is unchanged 
but Km(app) is increased). This suggests that 
quercetin, EGCG and ECG inhibit GLUT1-
mediated sugar uptake by binding at the exo-
facial 3MG binding site or at a site whose oc-
cupancy is mutually exclusive with 3MG oc-
cupancy of the exofacial sugar binding site. 
Consistent with this idea, the flavonoids act as 
noncompetitive inhibitors of net 3MG exit: 
they are without effect on Km(app) (12.9 mM) 
for exit, but decrease Vmax for exit by more 
than 2-fold from 2.03 mmol/L cell water/min 
to 0.89 (quercetin), 0.72 (EGCG), and 0.60 
mmol/L cell water/min (ECG; Figure 2B). 
We have previously shown that low concentra-
tions of exofacial inhibitors (e.g. WZB117 and 
maltose) or endofacial inhibitors (e.g cytocha-
lasin B) of GLUT1-mediated sugar transport 
modestly stimulate red cell sugar uptake (20, 
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29, 30). Consistent with these reports, 
quercetin (≤ 0.5 µM), EGCG (≤ 2.5 µM) and 
ECG (≤ 0.5 µM) reproducibly stimulate ery-
throcyte zero-trans 3MG uptake by up to 35% 
(p < 0.05; Figure 3). These results suggest that 
GLUT1 presents at least 2 exofacial flavonoid 
binding sites – one that stimulates sugar up-
take and a second site that inhibits uptake.  
CB is a membrane-permeant, GLUT1 in-
hibitor which binds at or close to the endofa-
cial glucose binding site (26, 27).  Extracellu-
lar maltose, but not glucose, inhibits equilibri-
um binding of the CB to the endofacial glu-
cose binding site of GLUT1 (29, 31, 32). We 
therefore asked if the flavonoids, which appear 
to act as exofacial ligands, also interfere with 
GLUT1 equilibrium [3H]-CB binding. 
Quercetin, EGCG, ECG, and nonradioactive 
CB inhibit [3H]-CB binding to GLUT1 with 
Ki(app) (assuming simple inhibition (33)) of 
0.637 ± 0.071 µM, 6.097 ± 0.726 µM, 0.871 ± 
0.103 µM, and 0.055 ± 0.003 µM respectively 
(Figure 4A). While these curve fits produce 
good correlation coefficients (R2 > 0.91 in all 
cases), the standard deviation of the residuals 
of each fit (≥ 0.09; excluding CB) is greater 
than 20% of the standard deviation of the y 
values suggesting that the fits are poor.  
Closer examination reveals that inhibition by 
quercetin and EGCG increases more steeply 
while inhibition produced by ECG increases 
less steeply than is expected for simple. 
Michaelis-Menten inhibition. Inhibition of 
radiolabeled CB binding by unlabeled CB is 
well-described by simple, Michaelis-Menten 
inhibition. We therefore asked if quercetin, 
EGCG and ECG inhibition of CB binding are 
better approximated by inhibition involving 
multiple, cooperative ligand binding sites and 
applied a simple, Hill-type model (33) to ana-
lyze these results (Figure 4B). This analysis 
produces fits with residuals that do not deviate 
significantly from zero and the standard devia-
tion of the residuals is significantly reduced. 
The analysis indicates that quercetin, EGCG, 
ECG and CB interact with Hill Coefficients (n, 
(34)) of 1.49 ± 0.13, 1.41 ± 0.16, 0.75 ± 0.08 
and 0.99 ± 0.05 sites per CB binding site re-
spectively with inhibitory constants (K’) of 
1.02 ± 0.10, 23.75 ± 9.07, 1.24 ± 0.12 and 
0.10 ± 0.01 µM respectively. Hill coefficients 
greater than 1 indicate multiple ligand binding 
sites interacting with positive cooperativity 
whereas Hill coefficients significantly less 
than 1 indicate multiple ligand binding sites 
(34) but could may also indicate multiple sites 
which interact with negative cooperativity 
(33,34). Application of the Extra Sum of 
Squares F-test (28) indicates for the range of 
inhibitor concentrations used, that the Hill-
model provides a significantly better fit for 
quercetin (p = 0.0002), EGCG (p = 0.0033) 
and ECG (p = 0.0084) data sets than the sim-
ple inhibition model but that both models ade-
quately describe inhibition of [3H]-CB binding 
by unlabeled CB. 
To further test the effects of flavonoids on CB 
binding to erythrocyte GLUT1, we measured 
the concentration dependence of CB inhibition 
of 3MG (0.1 mM) uptake ± flavonoids. The 
presence of quercetin (2 µM), EGCG (20 µM) 
or ECG (5 µM) inhibits basal sugar uptake 
(uptake in the absence of CB) and increases 
Ki(app) for CB inhibition of 3MG uptake by at 
least 2.5-fold (Figure 4C). Assuming simple 
competition between the flavonoids and CB 
for binding to GLUT1 (but see Figure 4B), the 
computed Ki(app) for quercetin (2 µM), EGCG 
(20 µM) and ECG (5 µM) inhibition of CB 
inhibition (Ki(app) = 0.24 ± 0.03 µM) of trans-
port are 1.88 ± 0.33, 9.63 ± 1.95 and 1.90 ± 
0.32 µM respectively. These results indicate 
that exofacial inhibitors impair CB binding to 
the GLUT1 endofacial sugar binding site and 
thereby reduce the potency of CB inhibition of 
sugar transport.  
To act as cytoplasmic antioxidants, the 
flavonoids must cross the cell membrane. Pre-
vious studies have suggested that dietary 
flavonoids enter cells both by protein-inde-
pendent trans-bilayer diffusion (35, 36), and 
via carrier proteins, including GLUT1, 
GLUT4, SGLT1 and MCT (15, 37–40).  
Incubation of RBCs with 1 µM [3H]-quercetin 
at 4ºC for 0.25 to 30 minutes indicates that the 
flavonoid achieves equilibrium association 
with RBCs within 30 seconds of exposure to 
the cells. The [3H]-quercetin equilibrium space 
of the cells is 70% of the equilibrium 
[3H]-3MG space of RBCs (Figure 5A). If 
quercetin enters cells via GLUT1, as suggest-
ed by Cunningham et al (15), [3H]-quercetin 
uptake in human erythrocytes should be inhib-
ited by inhibitors of sugar transport. CB (20 
µM) almost completely inhibits [3H]-3MG 
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uptake, but is without effect on [3H]-quercetin 
association with human RBCs (Figure 5B).  
We investigated potential interactions of β-D-
glucose, quercetin, EGCG and ECG with the 
exofacial sugar binding site by molecular 
docking using the homology modeled GLUT1 
outward-open structure (GLUT1-e2; ((18)). 
The exofacial, interstitium-exposed cavity of 
GLUT1-e2 presents 3 potential β-D-glucose 
docking sites - peripheral, intermediate and 
core (18, 20). Benzene ring A (Figure 1A–D) 
in quercetin, EGCG and ECG overlaps with 
the proposed core β-D-glucose docking site 
((20); and Figure 6A–D) while benzene ring B 
in quercetin interacts with intermediate and 
peripheral sites via hydrogen bonding and/or 
hydrophobic interactions (Figure 6B). In 
EGCG and ECG, benzene ring B is inverted 
45º, and makes additional interactions with the 
core β-D-glucose docking site, while their gal-
late group overlaps with the intermediate β-D-
glucose docking site (Figures 6C & D). 
The residues contributing to β-D-glucose 
docking at core, intermediate, and peripheral 
β-D-glucose sites have been previously de-
scribed (20). Figures 6E–H illustrate the puta-
tive hydrogen bond and hydrophobic contacts 
of core β-D-glucose, quercetin, EGCG and 
ECG with GLUT1-e2. All ligands form 5 
common hydrophobic interactions (Ile164, 
Val165, Ile168, Phe291 & Phe379), and 1 hy-
drogen bond interaction at Glu380 (Figures 
6E-H). Additionally, each inhibitor forms hy-
drogen bonds with Asn34 and Gln283 (Figures 
6F–H), but quercetin forms 3 additional hy-
drogen bonds (Gln283, Glu380 and Asn415; 
Figure 6F). EGCG and ECG form more hy-
drophobic contacts with GLUT1-e2 than 
quercetin (Figure 6G & H). 
Neuronal GLUT3, and insulin-sensitive 
GLUT4 share 93% and 85% sequence similar-
ity with GLUT1 respectively (41). We there-
fore asked if quercetin, EGCG and ECG inhi-
bitions of GLUT3 and GLUT4 resemble their 
inhibition of GLUT1 or if these inhibitors 
present an unanticipated selectivity towards 
these proteins. We transiently expressed hG-
LUT1, hGLUT3 or hGLUT4 into HEK293 
cells and assayed for dose-dependent inhibi-
tion of 100 µM 2-deoxy-D-glucose (2DG) 
uptake at 37 ºC. Our previous studies have 
shown that heterologous expression of hG-
LUT1, hGLUT3 or hGLUT4 suppresses ex-
pression of endogenous GLUT3 message and 
protein in HEK293 cells (20). All experiments 
were paired and relative 2DG uptake (vi/vc) by 
HEK293 cells was expressed as a function of 
[flavonoid]. Over the range of concentrations 
used, quercetin and EGCG inhibit GLUT1-, 
GLUT3- and GLUT4-mediated 2DG uptake in 
HEK-293 cells (Figures 7A–B). ECG has a 
bimodal effect on 2DG uptake first stimulating 
then inhibiting transport (Figure 7C). The 
curves drawn through the hGLUT1 data 
(dashed lines) were computed using equation 
3 and the parameters computed for flavonoid 
inhibitions of RBC-mediated 3MG transport 
shown in Fig 3. Notwithstanding the limited 
dose response range of Figure 7A, the use of a 
different substrate (2DG vs 3MG) and the ele-
vated assay temperature (37 vs 4ºC) where the 
flavonoids are susceptible to more rapid de-
composition (42), the agreement between 
flavonoid-inhibitions of heterologously ex-
pressed hGLUT1 and RBC-resident hGLUT1 
is strong. The curves drawn through the hG-
LUT3 and hGLUT4 data (solid lines) were 
computed by nonlinear regression using equa-
tion 3. Table 1 summarizes our findings. 
Quercetin shows higher affinity for GLUT1 
and GLUT4 than it does for GLUT3. EGCG 
displays similar avidity for GLUTs 1, 3 and 4. 
Relative to quercetin and EGCG, ECG has 
lower affinity for GLUTs 1, 3 and 4.  
Docking of quercetin, EGCG and ECG to exo-
facial GLUT3 and GLUT4 reveals that these 
ligands coordinate with equivalent residues 
when docked to the same GLUT isoform, but 
differ significantly when their interactions are 
compared across GLUT1, GLUT3 and 
GLUT4 (Figure 8). 
Discussion 
Red wine and green tea flavonoids inhibit the 
facilitative glucose transporter, GLUT1, by 
interacting at its exofacial sugar binding site. 
Quercetin, EGCG and ECG competitively in-
hibit net sugar uptake by human erythrocytes 
but are noncompetitive inhibitors of red cell 
sugar exit. Molecular docking studies using 
homology modeled GLUT1 reveal that 
quercetin, EGCG, ECG and D-glucose share 
overlapping interaction sites in the exofacial 
ligand binding cavity of GLUT1. While dock-
ing studies suggest that only one flavonoid can 
!4
 at U
niversity of M
assachusetts M
edical Center/The Lam
ar Soutter Library on D
ecem
ber 10, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
bind to GLUT1 at any instant, sugar transport 
and ligand binding studies indicate that the 
erythrocyte sugar transporter can bind at least 
two flavonoid molecules simultaneously. 
The sidedness of flavonoid action (exofacial) 
is compatible with previous reports suggesting 
that quercetin (21, 24), and EGCG (16) act as 
competitive inhibitors of GLUT1-mediated 
sugar uptake. Consistent with this conclusion, 
molecular docking analysis suggests that 
quercetin, EGCG and ECG share overlapping 
interaction envelopes in the exofacial ligand 
binding cavity of GLUT1-e2 including the 
previously defined core β-D-glucose interac-
tion site ((20), Figure 6). Docking analysis 
also suggests that flavonoid binding is coordi-
nated by the side chains of amino acids which 
form the previously defined exofacial inter-
mediate and peripheral β-D-glucose interac-
tion sites. The validity of our docking analysis 
is bolstered by the finding that the coordina-
tion of β-D-glucose at the core site in homolo-
gy modeled GLUT1-e2 involves the same 
amino acid residues coordinating β-D-glucose 
binding in the β-D-glucose-human GLUT3-e2 
crystal complex (42). Core β-D-glucose, 
quercetin, EGCG and ECG all form hy-
drophobic interactions with GLUT1 Ile164, 
Val165, Ile168, Phe291 and Phe379; and form 
a hydrogen bond with Glu380, suggesting that 
these residues are integral to ligand binding in 
the exofacial cavity. The chemical structures 
of EGCG and ECG are almost identical (the 
one difference being addition of a hydroxyl 
group at C3’ in EGCG) yet our docking analy-
sis reveals no striking differences in EGCG 
and ECG coordination to GLUT1-e2. Not-
withstanding, EGCG inhibits GLUT1 with 5-
fold lower affinity than ECG illustrating the 
limitations of this docking analysis. 
Prior equilibrium ligand binding studies 
demonstrate that extracellular maltose inhibits 
CB binding at the GLUT1 endofacial sugar 
binding site (27, 29). Here we show that exo-
facial quercetin, EGCG and ECG have the 
same effect. Ki(app) for inhibition of CB bind-
ing is 1.6 – 3 fold lower than Ki(app) for trans-
port inhibition. This is not explained by com-
petition between inhibitor and transported 
sugar for binding at the exofacial site because 
GLUT1 saturation by 0.1 mM 3MG is less 
than 5% (Km(app) for 3MG = 2.4 mM; see Fig-
ure 2A). Closer review of flavonoid inhibition 
of CB binding indicates that Sy.x (root mean 
square error) for curve fits to the simple inhi-
bition model are poor. Fitting the data to a Hill 
model comprising multiple cooperative bind-
ing sites ((33), equation 5) produces signifi-
cantly better fits for quercetin, EGCG or ECG 
but not for CB. Moreover, using the Extra 
Sum of Squares F-test (28) to test the null hy-
pothesis that the simple inhibition and Hill 
models provide equally good fits of the bind-
ing data fails for quercetin, EGCG or ECG. 
These results suggest that GLUT1 CB binding 
is affected by at least 2 positively cooperative 
binding sites each for quercetin and EGCG 
and two or more (possibly negatively coopera-
tive) binding sites for ECG (32, 33). If multi-
ple, exofacial flavonoid binding sites exist, 
docking analysis suggests they are unlikely to 
co-exist within the same GLUT1 molecule. 
Rather, they must be present in adjacent mole-
cules which interact with each cytochalasin B 
binding GLUT1 protein. 
We also considered that flavonoids compete 
directly with CB for binding at the endofacial 
sugar binding site. This would explain their 
displacement of CB from GLUT1 and would 
also be consistent with demonstrations of co-
operativity between endofacial ligand binding 
sites present in adjacent GLUT1 subunits of 
the GLUT1 tetramer  (29, 30, 44, 45). Molecu-
lar docking of CB and quercetin to the endofa-
cial orientation of GLUT1 (GLUT1-e1; (46)) 
supports the hypothesis that CB and quercetin 
could compete for high affinity binding to 
GLUT1 (not shown). However, inhibition of 
transport by a molecule that can bind with 
equal avidity to both exo- and endofacial sugar 
binding sites should produce noncompetitive 
inhibition of both net uptake or net exit (26, 
27). Since flavonoid inhibition of net uptake is 
competitive, this possibility is refuted. If an 
inhibitor were to bind with significantly lower 
affinity to the endofacial binding site versus 
the exofacial site, it would not only increase 
Km(app) for net sugar uptake but also reduce 
Vmax for uptake by > 65% (26, 27) and this is 
not observed. 
The actions of the flavonoids on sugar trans-
port demonstrate an additional form of coop-
erativity which we term cis-allostery (18). 
Quercetin, EGCG and ECG, like other exofa-
cial GLUT1 inhibitors (e.g WZB117; (20) and 
maltose (29)), stimulate GLUT1-mediated 
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sugar uptake at low inhibitor concentrations 
then inhibit transport as their concentration is 
raised. This reinforces the idea that at least 2 
flavonoid binding sites modulate GLUT1 
function. Two possibilities exist: 1) One of 
these sites is presented by GLUT1 and the 
second by a non-GLUT1 but nevertheless 
GLUT1-interacting protein; 2) The flavonoid 
binding sites exist on individual GLUT1 mol-
ecules whose adjacency in the GLUT1 ho-
motetramer (20, 29, 30) results in cooperative 
interactions. In both instances, flavonoid bind-
ing at the first, high affinity site stimulates 
sugar uptake by flavonoid-free GLUT1 mole-
cules. As flavonoid concentration is raised, 
ligand and sugar now compete for binding at 
the GLUT1 exofacial sugar binding site and 
transport is inhibited. While the former hy-
pothesis cannot be eliminated by the current 
study, our previous ligand binding (18, 20, 27, 
29-32, 43), hydrodynamic analyses (44, 47), 
biochemical cross-linking (48), freeze-fracture 
E.M. (47) and co-immunoprecipitation (49) 
studies of membrane-resident and purified 
GLUT1 support the latter hypothesis. 
Studies with heterologously expressed 
GLUT1, GLUT3 and GLUT4 indicate that 
quercetin inhibits GLUT1 and GLUT4 with 
comparable avidity but is up to 9-fold less po-
tent against GLUT3. EGCG shows similar 
inhibitory potency towards GLUT1, GLUT3 
and GLUT4. ECG appears to be only a very 
poor inhibitor of sugar uptake in GLUT1-, 
GLUT3- or GLUT4-expressing HEK293 cells 
but this conclusion should be tempered by the 
ligand’s reported instability at 37ºC (42). 
GLUT1 inhibition at high flavonoid concen-
trations could explain the anti-cancer action of 
flavonoids. Small molecule inhibition of cellu-
lar sugar transport results in a cascade of 
downstream events including down-regulation 
of glycolytic enzymes, cell cycle arrest, and 
ultimately, cell death (49). GLUT1-stimulation 
by low concentrations of flavonoids could ex-
plain their protective actions against diseases 
such as diabetes (50-53) and neurodegenera-
tive diseases (54-57), where enhanced cellular 
glucose uptake could be ameliorative. Howev-
er, flavonoids also directly or indirectly modu-
late other cellular targets including MAP ki-
nase, CDKs, HIF-1α, and vimentin (14). 
While some studies suggest that flavonoids 
may not readily cross the plasma membrane 
(58), others suggest that flavonoids enter cells 
via carrier proteins including SGLT1 (37, 38, 
59, 60), MCTs (39), GLUT1 (15) and GLUT4 
(40) or via transbilayer diffusion (35, 36).  The 
current study indicates that, while quercetin 
may cross the plasma membrane, it does so via 
a CB-insensitive, GLUT1-independent path-
way.  
While some health benefits of the flavonoids 
may derive from their anti-oxidant capacities, 
the dual actions of flavonoids on glucose 
transport (interaction with the exofacial sugar 
binding site and at regulatory sites which 
modulate sugar transport) present new tools to 
explore glucose transporter function and 
downstream glucose metabolism in tumors, in 
insulin-secreting and responsive tissues and in 
the CNS. 
Experimental Procedures 
Reagents 
Tritium-labeled 3-O-methylglucose 
([3H]-3MG), 2-deoxy-D-glucose ([3H]-2DG) 
cytochalasin B ([3H]-CB) and quercetin ([3H]-
quercetin) were purchased from American Ra-
diolabeled Chemicals (St. Louis, MO). Unla-
beled 3MG, CB, quercetin, (-)-epigallocate-
chin gallate (EGCG), (-)-epicatechin gallate 
(ECG) and phloretin were purchased from 
Sigma-Aldrich (St. Louis, MO). Phosphate-
buffered saline (PBS) was purchased from 
Thermo Fisher Scientific (Waltham, MA). 
WZB117 was purchased from EMD Millipore 
(Billerica, MA). 
Solutions  
KCl medium comprised 150 mM KCl, 5 mM 
HEPES, 0.5 mM EDTA, pH 7.4. Stop solution 
comprised ice-cold KCl medium plus 50 µM 
WZB117 and 100 µM phloretin. Sugar uptake/
exit medium was made up in KCl medium 
containing 0 – 20 mM 3MG ± inhibitors and 
contained [3H]-3MG or [3H]-quercetin as indi-
cated. HEK293 solubilization buffer com-
prised KCl medium with 1% Triton X-100. 
Cells 
De-identified whole human blood was pur-
chased from Biological Specialty Corporation 
(Colmar, PA). HEK293 cells were maintained 
in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine 
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serum, 100 units/mL penicillin, and 100 µg/
mL streptomycin in a 37 °C humidified 5% 
CO2 incubator. 
Heterologous expression of GLUTs 
Heterologous expression of hGLUT1, hG-
LUT3 and hGLUT4 in HEK293 cells was as 
previously described (49, 61). Both hGLUT1 
and hGLUT4 contain a myc-epitope in exofa-
cial loop 1 (61), while the 13 C-terminal 
amino acids in hGLUT3 are replaced by the 
corresponding residues of hGLUT4 (49) to 
facilitate detection of heterologously ex-
pressed transporter. 
Red blood cell sugar transport measurements 
All human erythrocytes sugar transport exper-
iments were performed at 4 ºC as previously 
described (20, 49). Red blood cells were iso-
lated from whole blood, and glucose-depleted 
as described previously (62). Sugar transport 
and ligand binding experiments reported be-
low typically involve addition of 2 to 10 vol-
umes of uptake or ligand binding medium ± 
inhibitor to 1 volume of a 50% suspension of 
red cells. Our measurements show that pre-
incubating RBCs with increasing volumes of 
medium containing the test inhibitor, progres-
sively reduces Ki(app) for inhibition of sugar 
transport or cytochalasin B binding. The ex-
planation (44) is that the very high GLUT1 
content of RBCs depletes [inhibitor]free as it 
interacts with GLUT1 resulting in an [in-
hibitor]free ≤ [inhibitor]total at the time of trans-
port or ligand binding assay. The most practi-
cal solution to this problem is to pre-incubate 
RBCs with excess volume of uptake or ligand 
binding medium lacking sugar or CB but con-
taining the inhibitor at the requisite concentra-
tion. We observe that Ki(app) for test compound 
inhibition of sugar transport or CB binding 
approaches its minimum asymptote when 
preincubation conditions are 1 volume of 
RBCs to 50 - 400 volumes of preincubation 
assay medium (the necessary dilution falls 
with increasing [inhibitor]total). We therefore 
pre-incubated RBCs with 50-400 volumes of 
assay medium prior to centrifugation and re-
suspension in uptake or ligand binding medi-
um to ensure optimal equilibration of inhibitor 
with GLUT1 before performing transport or 
ligand binding measurements. 
Zero-trans uptake 
Zero-trans [3H]-3MG or [3H]-quercetin uptake 
(uptake into cells lacking intracellular sugar or 
quercetin) was initiated by adding 10 volumes 
(100 µL) of uptake medium ± inhibitor to 1 
volume (10 µL) of sugar-depleted, 50% hema-
tocrit (Ht) red cells, and sugar uptake allowed 
to proceed for 30 – 60 seconds at 4 ºC. Uptake 
was stopped by adding 50 volumes (1 mL) of 
ice-cold stop solution containing 50 µM 
WZB117 and 100 µM phloretin. Cells were 
washed one more time in stop solution, lysed 
in 3% perchloric acid, and radioactivity as-
sayed for in clarified lysates using liquid scin-
tillation counting. Radioactivity measurements 
were done in duplicates. 
Zero-trans exit 
Glucose-depleted, packed RBCs were loaded 
with 10 mM 3MG by incubating 1 volume of 
cells with 20 volumes of 20 mM 3MG (con-
taining 1 µCi [3H]-3MG/mL of cold 3MG) for 
1 hour at 37 ºC. Immediately following 3MG 
loading, cells were transferred to 4 ºC and pre-
incubated with or without inhibitors for 10 – 
15 min. Cell suspension were spun at 10,000 x 
g for 1 min, and supernatant discarded. One 
volume (0.5 mL) of sugar-loaded RBCs were 
added to 50 volumes of KCl medium ± in-
hibitor on a shaker with magnetic stirrer. 
Aliquots (0.5 mL) of the suspension were 
withdrawn at indicated time intervals, and 
immediately added to 1 mL ice-cold stop solu-
tion. Cells were washed again in stop solution, 
lysed in 3% perchloric acid and assayed in 
duplicate for radioactivity.  
Hek293 cells sugar uptake 
All HEK293 cell sugar uptake measurements 
were performed at 37 ºC, using 100 µM 2-de-
oxyglucose (2DG plus [3H]-2DG) as described 
previously (49, 63). 
Equilibrium CB binding 
CB binding to human red cells was performed 
as previously described (20, 31). Briefly, 50 
µL of sugar-depleted RBC (50% Ht) ± in-
hibitors were mixed with 50 µL of ice-cold 
KCl medium containing 40 nM [3H]-CB and 
10 µM cytochalasin D for 15 min at 4 ºC, with 
constant end-over-end rotation. Total [CB] 
was obtained from 2 x 10 µL of the cell sus-
pension lysed in 100 µL of 3% perchloric acid, 
and radioactivity assayed for by liquid scintil-
lation counting. To obtain free [CB], cell sus-
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pension was centrifuged at 10,000 x g for 30 s, 
and 2 x 10 µL of clarified supernatant were 
assayed for radioactivity. Bound [CB] was 
calculated as Total [CB] – Free [CB]. 
Homology modeling 
The homology models of the outward-open 
(e2) conformations of GLUT1 and GLUT4 
were generated using the maltose-bound hu-
man GLUT3 structure (PDB code: 4ZWC) 
(42). Maltose was removed from the GLUT3 
structure and chain A was used as the template 
for modeled structures.  Sequence alignments 
were generated using ClustalX (69). Homolo-
gy models were built using Modeller-9.9 (70) 
and analyzed using PROCHECK (71).   
Stochastic docking 
The crystal structure of outward-open hG-
LUT3-e2 (4ZWC) (42) was obtained from the 
protein databank (http://www.rcsb.org/pdb/
home/home.do). The structures for β-D-Glu-
cose, quercetin, EGCG and ECG were ob-
tained from Pubchem (https://pub-
chem.ncbi.nlm.nih.gov). Docking was per-
formed using the Schrodinger software suite. 
The protein structure was preprocessed with 
the Protein Preparation Wizard, bond orders 
were assigned, hydrogens added and the H-
bond network was optimized. The system was 
energy minimized using the OPLS 2005 force 
field. Ligand structures were prepared with the 
LigPrep module and the pKa of the ligands 
was calculated using the Epik module. Molec-
ular docking was performed by the GLIDE 
module in standard-precision (SP) mode and 
default values for grid generation. Cavities for 
docking were calculated using the CastP 
server (http://sts.bioe.uic.edu/castp/) and the 
grid was centered on the residues forming the 
cavity. No restraints were used during the 
docking.  
Data analysis 
Linear and nonlinear regression analysis of 
data sets and statistical tests were performed 
using GraphPad Prism (Version 7.0a; La Jolla, 
CA). 
Michaelis-Menten inhibition of sugar transport 
is assumed to be described by:  
where vc is v measured in the absence of in-
hibitor I, [I] is the concentration of inhibitor 
and Ki(app) is that [I] producing 50% inhibition 
of uptake. 
Michaelis-Menten transport is assumed to be 
described by: 
where Vmax is the maximum rate of 3MG 
transport, [3MG] is the concentration of 3MG 
and Km(app) is the [3MG] where the rate of up-
take is Vmax /2. Sugar exit was analyzed by 
nonlinear regression analysis using Mathemat-
ica 10.4.1.0 (Wolfram Research) assuming that 
exit follows Michaelis-Menten kinetics and 
that the first derivative of the exit progress 
curve represents d[S]/dt at any given [3MG] 
(20). 
Transport stimulation followed by inhibition 
by inhibitors was approximated first by nor-
malizing all uptake to vc and then using the 
following model: 
where vc is uptake measured in the absence of 
inhibitor I, vi is uptake measured in the pres-
(equation 1)
(equation 2)
(equation 
3)
!8
 at U
niversity of M
assachusetts M
edical Center/The Lam
ar Soutter Library on D
ecem
ber 10, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ence of inhibitor, [I] is the concentration of 
inhibitor and Const1 through Const4 are model 
dependent (19). 
Inhibition of [3H]-CB binding to GLUT1 by 
ligands was analyzed by simple competitive 
inhibition using the model: 
where [CB]ib is bound [CB] measured in the 
presence of inhibitor I, [CB]cb is bound [CB] 
measured in the absence of inhibitor, Ki(app) is 
the apparent inhibitory constant for inhibition 
of CB binding by inhibitor, I, and KCB is dis-
sociation constant for CB binding to GLUT1. 
CB binding was also analyzed using the Hill 
equation for inhibition of equilibrium binding 
in which the transporter is allowed to bind 
more than one molecule of competing ligand, I 
where [CB]ib is bound [CB] measured in the 
presence of inhibitor I, [CB]cb is bound [CB] 
measured in the absence of inhibitor, K’ is 
Kd(app) for I binding to GLUT1 to the power of 
n where n is the number of inhibitor binding 
sites. Comparisons of quality of model fits 
were made using the extra sum of squares F-
test (28) using GraphPad Prism. 
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Figure Legends 
Figure 1 
Chemical structures and dose-dependent inhibition of human erythrocyte zero-trans 3MG (0.1 
mM) uptake by quercetin, EGCG and ECG. A. The Flavan skeleton for over 4,000 identified 
flavonoids, including quercetin (B), epigallocatechin gallate (EGCG) (C), and epicatechin gallate 
(ECG) (D). E. Ordinate: 3MG uptake in mmol/L cell water/min; Abscissa: [Inhibitor] in µM. Re-
sults are shown for quercetin (●), EGCG (△), and ECG (▲). Each point represents the mean ± 
SEM of at least 3 duplicate measurements. The curves were computed by nonlinear regression 
assuming that uptake inhibition is described by equation 1 with the following results: quercetin-
treated cells (●): Ki(app) = 1.88 ± 0.33 µM, R2 = 0.92, standard error of regression = 0.01 mmol/L 
cell water/min; EGCG-treated cells (△): Ki(app) = 9.63 ± 1.95 µM, R2 = 0.87, standard error of 
regression = 0.01 mmol/L cell water/min; ECG-treated cells (▲): Ki(app) = 1.90 ± 0.32 µM, R2 = 
0.93 standard error of regression = 0.01 mmol/L cell water/min 
Figure 2 
Effects of quercetin on the concentration-dependence of zero-trans 3MG uptake (A) and zero-
trans 3MG exit (B). Results are shown for control cells (○), quercetin-treated cells (●), EGCG-
treated cells (△), and ECG-treated cells (▲). Each data point represents the mean ± SEM of at 
least 4 experiments measured in duplicate. A, Ordinate: 3MG uptake in mmol/L cell water/min; 
Abscissa: [3MG]o in mM. Curves were computed by nonlinear regression assuming uptake is de-
scribed by equation 2. The results are summarized in Table 1. Inset shows a Lineweaver-Burk 
transformation of the data. The lines were computed by linear regression and the results are also 
summarized in Table 1. B, Ordinate: [3MG]i in mmol/L cell water; Abscissa: Time in minutes. 
Curves were computed by numerical integration and nonlinear regression assuming Michaelis-
Menten exit kinetics (equation 2) with the following results: Control cells (○): Vmax = 2.03 mmol/
L cell water/min, Km(app) = 12.9 mM, normalized root mean square error (NRMSE) = 0.011; 
quercetin (2.5 µM) treatment (●): Vmax = 0.89 mmol/L cell water/min, Km(app)  = 12.7 mM, 
NRMSE = 0.022; EGCG (1 µM) treatment (△): Vmax = 0.71 mmol/L cell water/min, Km(app) = 
12.30 mM, NRMSE = 0.024; ECG (0.25 µM) treatment (▲): Vmax = 0.44 mmol/L cell water/min, 
Km(app) = 13.5 mM, NRMSE = 0.044. 
Figure 3 
Sub-saturating concentrations of quercetin, EGCG, and ECG stimulate 3MG uptake. Ordinate: 
Relative 3MG uptake. Abscissa: Concentration of inhibitors in M (log scale). Results are shown 
for cells treated with quercetin (●), EGCG (△), and ECG (▲). Each data point represents the 
mean ± SEM of at least 3 duplicate measurements. The curves were computed by nonlinear re-
gression using equation 3 and the parameters producing the best fits are summarized in Table 2. 
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The following summarizes the quality of the fits: quercetin treatment (●):R2 = 0.966, standard 
error of regression (Sy.X) = 0.097; EGCG treatment (△): R2 = 0.923, sSy.X = 0.128; ECG treat-
ment (▲): R2 = 0.866, Sy.X = 0.158. 
Figure 4 
Flavonoids inhibit CB binding to human RBCs. A. Inhibition of [3H]-CB binding to human 
RBCs. Ordinate: Normalized ratio of bound [3H]-CB to free [3H]-CB. Abscissa:  [inhibitor],µM 
(log scale). Results are shown for cells treated with quercetin (●), EGCG (△), ECG (▲) and 
non-radioactive CB (○). Each data point represents the mean ± SEM of 3 separate duplicate ex-
periments. Curves were computed by nonlinear regression using equation 4 assuming [[3H]-CB] 
= 0.05 µM and KCB = 0.055 µM, with the following results: quercetin treatment (●): Ki(app) = 0.55 
± 0.06 µM, R2 = 0.948, standard error of regression (Sy.x) = 0.087; EGCG treatment (△): Ki(app) 
= 5.25 ± 0.63 µM, R2 = 0.949, Sy.x = 0.089; ECG treatment (▲): Ki(app) = 0.75 ± 0.09 µM, R2 = 
0.910, Sy.x = 0.094; nonradioactive CB treatment (○): Ki(app) = 0.055 ± 0.003 µM, R2 = 0.988, 
Sy.x = 0.036. The residuals of the quercetin, EGCG and ECG fits are plotted beneath the inhibi-
tion plot. B. Reanalysis of the same data set assuming multiple binding sites for competing ligand 
using the Hill-equation (equation 5). The results are: quercetin treatment (●): Ki(app) = 1.02 ± 0.09 
µM, n = 1.49 ± 0.13, R2 = 0.97, Sy.x = 0.064; EGCG treatment (△): Ki(app) = 23.75 ± 9.07 µM, n 
= 1.41 ± 0.16, R2 = 0.97, Sy.x = 0.074; ECG treatment (▲): Ki(app) = 1.24 ± 0.12 µM, n = 0.75 ± 
0.08, R2 = 0.94, Sy.x = 0.082; nonradioactive CB treatment (○): Ki(app) = 0.10 ± 0.01 µM, n = 0.99 
± 0.05, R2 = 0.99, Sy.x = 0.036. The residuals of the quercetin, EGCG and ECG fits are plotted 
beneath the inhibition plot. C. Ordinate: 3MG uptake in mmol/L cell water/min. Abscissa: Con-
centration of inhibitors in µM (log scale). Results are shown for CB-treated cells (○), and CB-
treated cells plus 2 µM quercetin (●), 20 µM EGCG (△) or 5 µM ECG (▲). Each data point rep-
resents the mean ± SEM of at least 3 duplicate measurements. Curves were computed by nonlin-
ear regression using equation 1 and have the following results: CB treatment (○): Ki(app) = 0.24 ± 
0.03 µM, R2 = 0.94, Sy.x = 0.007; CB + 2 µM quercetin (●): Ki(app) = 0.62 ± 0.17 µM, R2 = 0.83, 
Sy.x = 0.004; CB + 20 µM EGCG (△): Ki(app) = 0.619± 0.123 µM, R2 = 0.897, Sy.x = 0.004; CB 
+ 5 µM ECG (▲): Ki(app) = 0.71 ± 0.12 µM, R2 = 0.94, Sy.x = 0.002. 
Figure 5 
Quercetin uptake by RBCs. A. Relative [3H]-3MG and [3H]-quercetin spaces of RBCs. Ordinate: 
Equilibration relative to the equilibrated 3MG space of the cell. Equilibrium [3H]-quercetin (1 
µM) uptake is observed within 5 minutes of exposure to cells. [3H]-3MG (100 µM) equilibration 
is achieved after 30 minutes exposure. Each bar shows the mean ± S.E.M of 3 separate duplicate 
experiments. Unpaired t test analysis indicates: **, significant difference between the 3MG and 
quercetin cell volume (p = 0.0044). B. Effect of CB on [3H]-quercetin and [3H]-3MG uptake by 
human erythrocytes. Ordinate: Substrate uptake relative to control. Abscissa: Radiolabeled sub-
strate. Results are shown for control (□) and 20 µM CB-treated cells (■). Each bar shows the 
mean ± S.E.M of 3 separate experiments measured in duplicate. Unpaired t test analysis indicates: 
***, significant [3H]-3MG uptake inhibition by CB (p < 0.0005), n.s., no significant difference in 
[3H]-quercetin uptake with or without CB treatment (p > 0.05).  
Figure 6 
Molecular docking of β-D-glucose, quercetin, EGCG and ECG to homology-modeled exofacial 
GLUT1 conformation. A. Homology-modeled exofacial GLUT1 (GLUT1-e2) is shown in car-
toon representation, and membrane spanning helixes 1, 3-6, 8-10 are indicated. Ligands – periph-
eral, intermediate and core β-D-glucose (red, A, E); quercetin (cyan, B, F); EGCG (sky blue, C, 
G); ECG (light blue, D, H) – are shown as spheres complexed with GLUT1-e2. The insets zoom 
in to illustrate the spatial arrangement of ligand (shown in stick representation) interaction sites 
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within GLUT1-e2 but with the GLUT1-e2 cartoon eliminated. The boxes (E – F) illustrate β-D-
glucose (E), quercetin (F), EGCG (G) and ECG (H) coordination in the exofacial cavity showing 
residues that form hydrogen bonds and hydrophobic interactions. The analysis suggests that 
EGCG & ECG binding to GLUT1-e2 promotes a 45º flip of benzene ring B. 
Figure 7 
Isoform specificity of sugar transport inhibition by flavonoids. Results are shown for transport 
inhibition by quercetin (A), EGCG (B) and ECG (C) in transfected HEK293 cells transiently ex-
pressing hGLUT1 (●), hGLUT3 (△) or hGLUT4 (▲). Ordinate: relative 2-deoxyglcuose uptake 
(vi/vc); Abscissa: [inhibitor] in M (log scale). The dashed curves are the curves describing 
quercetin, EGCG and ECG modulations of hGLUT1-mediated 3MG uptake in RBCs at 4ºC (Fig-
ure 3) computed using equation 3. The parameters used were those used in Figure 3 with one ex-
ception. Const4 for ECG modulation of GLUT1 was reduced 7-fold. The solid curves describe 
flavonoid modulations of hGLUTs 3 and 4 and were computed by nonlinear regression using 
equation 3. The parameters describing the best fits are summarized in Table 2. The following 
summarizes the quality of these fits: quercetin treatment: hGLUT3 (△): R2 = 0.998, Sy.X = 
0.017; hGLUT4 (▲): R2 = 0.999, Sy.X = 0.008; EGCG treatment hGLUT3 (△): R2 = 0.998, 
Sy.X = 0.017; hGLUT4 (▲): R2 = 0.999, Sy.X = 0.008; ECG treatment: hGLUT3 (△): R2 = 
0.976, Sy.X = 0.048; hGLUT4 (▲): R2 = 0.482, Sy.X = 0.144. 2DG uptake in untreated, untrans-
fected cells averaged 2.7 ± 0.6 pmol/µg protein/min with a range of 1.6 – 3.8 pmol/µg protein/
min. hGLUT1, hGLUT3 and hGLUT4 heterologous expression increased basal 2DG uptake by 
6.3 ± 3.3, 3.4 ± 0.8 and 4.5 ± 1.5-fold respectively. 
Figure 8 
2-dimensional representation of ligands interactions with hm-GLUT1-e2, GLUT3-e2 and hm-
GLUT4-e2 interactions Residues within 4Å distance to docking ligand are shown for quercetin 
(A), EGCG (B) and ECG (C). Residues and contacts are shown in the following color codes: Po-
lar, blue; hydrophobic, green; negatively charged, orange; positively charged, violet; hydrogen 
bond and its directionality; purple arrow. Pi-stacking, green arrow; solvent exposed regions of 
ligands are indicated by gray-shaded circles. 
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1The data of Figure 2a were analyzed by 2nonlinear regression analysis assuming Michaelis-
Menten kinetics (equation 2) or by Lineweaver-Burk analysis which also assumes Michaelis-
Menten kinetics (Figure 2a inset). The resulting parameters (Vm and Km(app) for 3MG uptake) are 
shown as mean ± SD of the analysis. The fit statistics (standard error of regression (Sy.X) and R2) 
are also shown. 
1Table 1
Vm  (mM/min) Km(app) (mM) Sy.X (mM/min) R2
2Non Linear Regression Analysis using Michaelis Menten equation
Control 1.20 ± 0.08 2.39 ± 0.36 0.07 0.93
Quercetin 1.98 ± 0.66 11.07 ± 5.03 0.07 0.89
EGCG 2.14 ± 0.39 10.64 ± 2.63 0.05 0.97
ECG 1.72 ± 0.29 7.14 ± 1.85 0.07 0.94
3Lineweaver Burk Analysis
Control 0.95 ± 0.10 1.49 ± 0.24 0.06 1.00
Quercetin 0.68 ± 0.13 2.50 ± 0.04 0.46 0.99
EGCG 1.49 ± 0.17 3.59 ± 0.06 0.32 1.00
ECG 0.83 ± 0.13 2.51 ± 0.04 0.21 1.00
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Table 2 
1Inhibition of GLUT1-, GLUT3- and GLUT4-mediated 2DG uptake in 
HEK293 cells by quercetin, EGCG and ECG
2Inhibitor 3UTF 4GLUT1 5GLUT3 6GLUT4
7RBC-
GLUT1
Quercetin
IC50 (µM) 9.59 ± 1.42 2.00 ± 0.99 17.68 ± 1.71 1.70 ± 0.25 1.88 ± 0.33
Const1 (M-1) 8N/A (4.69 ± 1.92) x 10-5 0.47 ± 0.02
(7.59 ± 3.75) 
x 10-8
(4.69 ± 1.92) 
x 10-5
Const2 N/A (2.59 ± 0.05) x 104
(5.96 ± 0. 55) 
x 10-8
(5.95 ± 6.12) 
x 10-5
(2.59 ± 0.05) 
x 104
Const3 (M-1) N/A (1.79 ± 0.04) x 104
(2.77 ± 0.16) 
x 104
(2.37 ± 0.61) 
x 10-14
(1.79 ± 0.04) 
x 104
Const4 (M-2) N/A (1.17 ± 0.10) x 1010
(3.05 ± 0.55) 
x 108 507 ± 266
(1.17 ± 0.10) 
x 1010
EGCG
K0.5 (µM) 5.49 ± 1.86 9.09 ± 4.99 14.44 ± 8.19 8.45 ± 5.47 9.63 ± 1.95
Const1 (M-1) N/A 0.12 ± 0.03 0.28 ± 0.14 0.59 ± 0.48 0.12 ± 0.03
Const2 N/A (5.02 ± 0.33) x 104
(9.33 ± 0.53) 
x 103
(3.99 ± 2.44) 
x 104
(5.02 ± 0.33) 
x 104
Const3 (M-1) N/A (1.03 ± 0.33) x 104
6.2 ± 3.8 x 
10-7
(2.37 ± 0.76) 
x 107
(1.03 ± 0.33) 
x 104
Const4 (M-2) N/A (8.68 ± 0.78) x 109
4.76 ± 1.30x 
109
(1.98 ± 0.86) 
x 1010
(8.68 ± 0.78) 
x 109
ECG
K0.5 (µM) 5.54 ± 1.84 22.7 ± 17.3 199.4 ± 333.4 126.2 ± 106.3 1.90 ± 0.32
Const1 (M-1) N/A (5.24 ± 2.18) x 10-5
(8.37 ± 2.33) 
x 10-2
(4.39 ± 0.87) 
x 10-2
(5.24 ± 2.18) 
x 10-5
Const2 N/A (4.61± 0.17) x 104
(9.38 ± 0.18) 
x 104
(7.94 ± 0.85) 
x 103
(4.61± 0.17) x 
104
Const3 (M-1) N/A (4.14 ± 0.17) x 104
(4.63 ± 0.12) 
x 104
(6.14 ± 0.89) 
x 103
(4.14 ± 0.17) 
x 104
Const4 (M-2) N/A (2.48 ± 0.29) x 109
(9.54 ± 0.65) 
x 108
(1.06 ± 0.38) 
x 108
(1.84 ± 0.29) 
x 1010
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1The data of Figures 3 (3MG uptake at 4ºC) and 7 (2DG uptake at 37ºC) were analyzed by non-
linear regression assuming that uptake inhibition is described by equation 1 (to yield IC50) or by 
equation 3 (to yield Const1-4). 2Results are shown quercetin, EGCG and ECG-modulations of 
sugar transport. Assuming equation 3 describes intramolecular cis-allostery (19), Const1 and Con-
st3 have units of M-1, Const4  has units of M-2 and Const2  is dimensionless. Results are summa-
rized for 3untransfected cells, 4GLUT1-transfected cells, 5GLUT3-transfected cells, 6GLUT4-
transfected cells and, for comparison, for 7GLUT1-expressing human RBCs. 8Equation 3 analysis 
is not applicable to untransfected cells.
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inhibitors of GLUT1-mediated sugar uptake
Red wine and green tea flavonoids are cis-allosteric activators and competitive
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